REN001
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Mitochondrial Myopathy
Conditions
Primary Mitochondrial Myopathy
Trial Timeline
May 10, 2019 → Apr 23, 2020
NCT ID
NCT03862846About REN001
REN001 is a phase 1 stage product being developed by OnKure Therapeutics for Primary Mitochondrial Myopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03862846. Target conditions include Primary Mitochondrial Myopathy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05267574 | Phase 2/3 | Terminated |
| NCT04226274 | Phase 1 | Completed |
| NCT03862846 | Phase 1 | Terminated |
Competing Products
20 competing products in Primary Mitochondrial Myopathy